First National Trust Co Has $14.62 Million Stake in Eli Lilly and Company (NYSE:LLY)

First National Trust Co decreased its stake in Eli Lilly and Company (NYSE:LLY) by 1.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,081 shares of the company’s stock after selling 330 shares during the quarter. First National Trust Co’s holdings in Eli Lilly and Company were worth $14,620,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of LLY. Nadler Financial Group Inc. boosted its stake in Eli Lilly and Company by 6.8% in the 3rd quarter. Nadler Financial Group Inc. now owns 2,362 shares of the company’s stock valued at $1,269,000 after buying an additional 150 shares in the last quarter. Center for Financial Planning Inc. raised its position in Eli Lilly and Company by 26.5% in the 3rd quarter. Center for Financial Planning Inc. now owns 506 shares of the company’s stock valued at $272,000 after purchasing an additional 106 shares during the last quarter. Stonegate Investment Group LLC raised its position in Eli Lilly and Company by 0.8% in the 3rd quarter. Stonegate Investment Group LLC now owns 67,681 shares of the company’s stock valued at $36,354,000 after purchasing an additional 537 shares during the last quarter. Affinity Wealth Management LLC raised its position in Eli Lilly and Company by 1.8% in the 3rd quarter. Affinity Wealth Management LLC now owns 12,916 shares of the company’s stock valued at $6,937,000 after purchasing an additional 228 shares during the last quarter. Finally, Legacy Financial Group LLC bought a new position in Eli Lilly and Company in the 3rd quarter valued at $35,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 2.8 %

NYSE LLY traded down $20.94 on Friday, reaching $734.97. The company had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. Eli Lilly and Company has a 52 week low of $419.80 and a 52 week high of $800.78. The company has a quick ratio of 0.73, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The stock has a market cap of $698.52 billion, a price-to-earnings ratio of 108.24, a PEG ratio of 1.46 and a beta of 0.37. The stock’s 50 day moving average is $761.06 and its 200-day moving average is $671.38.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same period in the previous year, the firm earned $1.62 earnings per share. The company’s revenue was up 26.0% on a year-over-year basis. Equities analysts predict that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LLY has been the subject of several research analyst reports. Truist Financial lifted their price objective on Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research report on Wednesday. Morgan Stanley boosted their target price on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. BMO Capital Markets boosted their target price on Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research report on Wednesday. Wells Fargo & Company boosted their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Finally, TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and an average price target of $757.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.